EyePoint Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
EyePoint Pharmaceuticals's earnings have been declining at an average annual rate of -16.4%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 14.8% per year.
Key information
-16.4%
Earnings growth rate
20.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 14.8% |
| Return on equity | -47.3% |
| Net Margin | -226.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival
Jan 30EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 29% Share Price Plunge Could Signal Some Risk
Dec 13
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
Nov 14Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%
Oct 29EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price
Sep 13EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
Aug 29These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Aug 15EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 09Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%
Jun 19EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
May 06More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Aug 30Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD
Jul 15Revenue & Expenses Breakdown
How EyePoint Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 46 | -104 | 51 | 0 |
| 30 Jun 24 | 50 | -87 | 49 | 21 |
| 31 Mar 24 | 50 | -79 | 50 | 0 |
| 31 Dec 23 | 46 | -71 | 51 | 0 |
| 30 Sep 23 | 43 | -100 | 55 | 0 |
| 30 Jun 23 | 37 | -106 | 59 | 27 |
| 31 Mar 23 | 40 | -102 | 60 | 0 |
| 31 Dec 22 | 41 | -102 | 60 | 0 |
| 30 Sep 22 | 42 | -78 | 64 | 0 |
| 30 Jun 22 | 41 | -77 | 62 | 0 |
| 31 Mar 22 | 39 | -67 | 58 | 0 |
| 31 Dec 21 | 37 | -58 | 54 | 0 |
| 30 Sep 21 | 33 | -54 | 48 | 0 |
| 30 Jun 21 | 39 | -42 | 45 | 0 |
| 31 Mar 21 | 34 | -44 | 44 | 0 |
| 31 Dec 20 | 34 | -45 | 46 | 0 |
| 30 Sep 20 | 36 | -40 | 46 | 0 |
| 30 Jun 20 | 23 | -52 | 47 | 0 |
| 31 Mar 20 | 26 | -51 | 48 | 0 |
| 31 Dec 19 | 20 | -57 | 48 | 0 |
| 30 Sep 19 | 14 | -58 | 45 | 0 |
| 30 Jun 19 | 12 | -75 | 41 | 0 |
| 31 Mar 19 | 6 | -98 | 35 | 0 |
| 31 Dec 18 | 5 | -86 | 25 | 0 |
| 30 Sep 18 | 3 | -80 | 18 | 0 |
| 30 Jun 18 | 3 | -53 | 13 | 0 |
| 31 Mar 18 | 3 | -25 | 10 | 0 |
| 31 Dec 17 | 3 | -23 | 10 | 0 |
| 30 Sep 17 | 8 | -17 | 9 | 0 |
| 30 Jun 17 | 8 | -18 | 11 | 0 |
| 31 Mar 17 | 7 | -19 | 10 | 0 |
| 31 Dec 16 | 7 | -19 | 10 | 0 |
| 30 Sep 16 | 1 | -24 | 10 | 0 |
| 30 Jun 16 | 2 | -22 | 9 | 0 |
| 31 Mar 16 | 2 | -20 | 9 | 0 |
| 31 Dec 15 | 2 | -20 | 8 | 0 |
| 30 Sep 15 | 2 | -19 | 8 | 0 |
| 30 Jun 15 | 27 | 6 | 8 | 0 |
| 31 Mar 15 | 26 | 8 | 8 | 0 |
| 31 Dec 14 | 28 | 10 | 8 | 0 |
| 30 Sep 14 | 28 | 11 | 7 | 0 |
| 30 Jun 14 | 3 | -13 | 7 | 0 |
| 31 Mar 14 | 4 | -13 | 8 | 0 |
Quality Earnings: EYPT is currently unprofitable.
Growing Profit Margin: EYPT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EYPT is unprofitable, and losses have increased over the past 5 years at a rate of 16.4% per year.
Accelerating Growth: Unable to compare EYPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EYPT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (42%).
Return on Equity
High ROE: EYPT has a negative Return on Equity (-47.35%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 23:53 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
EyePoint Pharmaceuticals, Inc. is covered by 20 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Jennifer Kim | Cantor Fitzgerald & Co. |